These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614 [TBL] [Abstract][Full Text] [Related]
5. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells. Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236 [TBL] [Abstract][Full Text] [Related]
6. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629 [TBL] [Abstract][Full Text] [Related]
7. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147 [TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729 [TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308 [TBL] [Abstract][Full Text] [Related]
10. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma. Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487 [TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321 [TBL] [Abstract][Full Text] [Related]